StockWatch
·
SHALBY · Q2 FY27 · THE VERDICT

9% growth masks hospital margin squeeze; Gurgaon breakout doesn't offset core pressure

Revenue is on track for double-digit FY27, but the quarter exposed deep cracks: hospital EBITDA margin fell 130 bps YoY to 18.2%, missing the 20% target. Worse, PAT collapsed 24.9% QoQ while revenue fell only 5.4% — a leverage inversion that management never explained.

Q2 FY27 resultsSHALBYShalby Ltd07 Nov 2026 · 6 min read
Revenue QoQ

-5.4%

Sequential softness

PAT QoQ

-24.9%

4x the revenue decline

Hospital EBITDA margin

18.2%

vs 19.5% prior year, vs 20% target

On the headline, Shalby delivered 9.7% YoY revenue growth and 8.3% PAT growth — steady enough. But read the quarter sequentially and the picture inverts: revenue fell 5.4% QoQ, and profit crashed 24.9% QoQ. That 4x leverage collapse — where revenue barely declined but profit halved — signals either one-time Q2 costs or a procedure mix shift. Management didn't explain it, only deferred margin benefits to Q4.

The deeper issue is the hospital business. Stand-alone EBITDA margin compressed to 18.2% from 19.5% a year ago — a 130 bps erosion — while management is still publicly targeting 20% for FY27. That gap is no longer a rounding error. With occupancy at 52% and ARPOB growth only 4.3% YoY, the core franchise is not earning to its own guidance.

What held up on the call, and what didn't

Management's claims graded against actual results

Hospital business remains core, profitable activity with significant headroom

Overstated

Stand-alone margin 18.2% vs 19.5% YoY (−130 bps); target 20% now at risk

Gurgaon unit delivering strong growth trajectory, approaching breakeven

Supported

Revenue ~₹30 Cr (+50% YoY); EBITDA positive 2 consecutive quarters; occupancy 55%; ARPOB ₹96k (+18% YoY)

ROCE expansion progressing toward 11-13% industry standard

Contradicted

Annualized ROCE 9.4%; below guidance, no recovery timeline

MedTech targeting double-digit EBITDA margins post-regulatory changes

Overstated

EBITDA positive 5 consecutive quarters; no margin % disclosed; path to double-digit margins unquantified

Margin support expected from operational efficiencies and new supply chain model

Partial

EBITDA margin flat YoY at 14.6% vs 15.9%; hospital margin compressed despite efficiency initiatives

What changed vs. the prior quarter

  • Gurgaon unit accelerating upward

  • Revenue ~₹30 Cr (+50% YoY); EBITDA positive for 2 consecutive quarters; occupancy 55%; targeting PBT breakeven by Q3/Q4 FY27

  • Hospital margin pressured downward

  • Stand-alone margin 18.2% vs 19.5% YoY (−130 bps); vs 20% guidance target, now at risk. Cost pressures cited but no specific recovery timeline

  • ROCE guidance miss confirmed

  • Annualized ROCE 9.4% vs prior 11-13% target. Capex ROI deferred; no improvement timeline disclosed

  • MedTech profitability inflection

  • 5th consecutive quarter EBITDA positive; consolidated Q2 EBITDA ₹3.6 Cr vs ₹1.6 Cr Q1. Still no path to double-digit margins quantified

The bull-bear ledger

  • Gurgaon 50% growth; EBITDA positive 2 consecutive quarters — genuine execution on the new platform

  • MedTech EBITDA positive 5 consecutive quarters; new supply chain reducing COGS 30-40%; prior ₹165 Cr loss turning into margin contribution

  • Net debt declining (₹458 Cr vs ₹554 Cr YoY); gearing 0.45x; capex disciplined at ₹10 Cr per half

  • Occupancy rising to 52% from 48% YoY; specialist network expanding; ALOS improved to 3.58 days; runway for leverage

  • Hospital margin compressed 130 bps YoY; target of 20% now at risk; no clear path to recovery articulated

  • PAT -24.9% QoQ while revenue -5.4% QoQ; Q2-specific headwinds never explained; profit volatility higher than implied

  • ROCE at 9.4% vs 11-13% guidance; capex ROI underperforming or leverage limiting returns; no recovery timeline

  • MedTech: no quantified path to double-digit margins; management deferred numbers; turnaround narrative still unproven

  • Strategy ambiguity on hospital vs. MedTech vs. Gurgaon; hospital-only capex allocation not disclosed; analyst pushback deflected

Risks, ranked by holder concern

What could go wrong and why a shareholder should care

Hospital margin compression continues; 20% target now at risk

High

Core profit engine losing leverage. Margin fell 130 bps YoY and is tracking below guidance. If compression persists into Q3/Q4, the hospital thesis breaks and normalization of multiples likely.

ROCE below 11-13% guidance with no recovery timeline

High

Signals capex ROI underperforming or debt burden limiting returns. If capex cycles higher without ROI recovery, leverage rises and equity returns compress.

QoQ PAT collapse (-24.9% vs -5.4% revenue) unexplained; structural weakness possible

High

If Q2 cost pressures repeat, profit power is structurally lower than guided. If one-time, timing matters — but silence on the call raises credibility doubt on near-term visibility.

MedTech: no clear path to double-digit EBITDA margins disclosed

Medium

Prior ₹165 Cr loss; EBITDA positive but small (₹3.6 Cr). Management evasion ('unable to give you numbers') on roadmap raises doubt on execution confidence and turnaround credibility.

Gurgaon unit dependency; PBT breakeven by Q3/Q4 FY27 is tight timeline

Medium

Unit is only ~10% of hospital revenue; 50% growth is impressive but scale still small. If occupancy growth stalls or costs rise, breakeven gets pushed and capex ROI declines.

Hospital occupancy at 52% still below potential; execution risk if improvement slows

Medium

Management claims '50% revenue upside at full utilization,' but occupancy growth has only +400 bps YoY and momentum is unclear. If occupancy stalls, margin recovery thesis loses its key lever.

NPPPA drug capping effective mid-November 2026; oncology margin risk

Low

Management expects limited impact (medicines bundled in surgeries), but if implementation is stricter or affects implant-related pharma, margins compress unexpectedly.

How the street is positioned

The stock has lost 65% from its all-time high of ₹339.5 and is now trading at ₹118.35, well below all three major simple moving averages (SMA20 ₹123.35, SMA50 ₹135.86, SMA200 ₹155.05). The RSI at 35.9 shows weak momentum. Near the 52-week low of ₹110.61, the stock has recovered 7% off lows but is still deeply beaten. This drawdown prices in either structural profit loss or a permanent de-rating of multiples.

On the ownership side, FII holdings are steady at 4.46% (up 0.1pp from Q1), and promoter is locked in at 74.33%. No material selling pressure from institutions; if anything, the slight FII uptick suggests some accumulation at depressed levels. But the framing remains cautious — no enthusiastic call from any major holder yet.

The paradox is stark: the stock is cheap by absolute valuation (near 52-week low), but the quarter's miss on hospital margin guidance and the unexplained QoQ PAT collapse have shattered execution credibility. The 65% loss from ATH is no longer speculative froth; it's pricing in a permanent earnings reset. This quarter — rather than sparking a relief bounce — reinforced the bear thesis: hospital margins are compressing, not recovering, and management has no clear answer.

The debate

What to watch next

Three numbers that resolve the debate in Q3/Q4 FY27
  • 1 · Hospital EBITDA margin stabilizes or improves

    Must recover to at least 19%+ in Q3 to restore guidance credibility. Current 18.2% and compressing trend (three quarters down) signals structural pressure, not cyclical. If margin continues lower into Q3, the 20% target is abandoned and re-rating accelerates.

  • 2 · Gurgaon unit achieves PBT breakeven by Q3/Q4 FY27

    Management's tight guidance on this timeline will determine execution credibility on the new platform. Occupancy at 55% has room to run; if it slows or costs rise, breakeven slips and capex ROI questions deepen.

  • 3 · MedTech supply chain cost benefits flow through in H2 FY27

    Management promised 30-40% COGS reduction and targeted full benefits by Q4. Consolidated EBITDA doubled from Q1 to Q2 (₹1.6 Cr → ₹3.6 Cr), but margins are still small. H2 results will show if the turnaround is real or just seasonal volatility.

Shalby is at an inflection point: the old hospital-only story is compressing (margin, ROCE), but the new multi-platform story (Gurgaon, MedTech) is still too small to carry earnings. This quarter exposed the gap. Gurgaon is genuine progress, but at ₹30 Cr revenue (~10% of hospital base), it cannot yet offset hospital margin erosion.

The single number to track from here is hospital EBITDA margin. At 18.2% and falling, it is below guidance and raising doubt on whether management's efficiency and specialist expansion thesis is real execution or just talk. If margin stabilizes or improves in Q3/Q4, the bull case holds and the stock finds support. If it compresses further, the 65% loss from ATH was only the first leg of re-rating.

Rating: Hold. The debate is unresolved; execution in Q3/Q4 FY27 will decide whether this is a cyclical stumble (opportunity) or a structural reset (risk).

Informational and educational content only. Not investment advice.